1-((4-(trifluoromethyl)phenyl)sulfonyl)piperazine | 793679-07-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-((4-(trifluoromethyl)phenyl)sulfonyl)piperazine
• 英文别名: 1-[4-(Trifluoromethyl)benzenesulfonyl]piperazine；1-[4-(trifluoromethyl)phenyl]sulfonylpiperazine
• CAS: 793679-07-9
• 化学式: C₁₁H₁₃F₃N₂O₂S
• mdl: MFCD06363488
• 分子量: 294.298
• InChiKey: SQXBFRFABWYXTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  57.8
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1-((4-(trifluoromethyl)phenyl)sulfonyl)piperazine 在 sodium tetrahydroborate 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 73.5h， 生成 1-benzo[b]thiophen-3-yl-3-[4-(4-trifluoromethylbenzenesulfonyl)piperazin-1-yl]-ol
  参考文献：
  名称：

  Novel Benzo[b]thiophene Derivatives as New Potential Antidepressants with Rapid Onset of Action

  摘要：

  We report benzo[b]thiophene derivatives synthesized according 10 a dual strategy. 8j, 9c, and 9e with affinity values toward 5-HT(7)R and 5-HTT were selected to probe their antidepressant activity in vivo using the forced swimming text (FST). The results slowed significant antidepressant activity after chronic treatment. 9c was effective in reducing the immobility time in FST even after acute treatment. These findings identify these compounds as a new class of antidepressants with a rapid onset of action.

  DOI：

  10.1021/jm2000773
• 作为产物：
  描述：

  4-三氟甲基苯磺酰氯 在 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 1-((4-(trifluoromethyl)phenyl)sulfonyl)piperazine
  参考文献：
  名称：

  首次发现含有磺酰胺部分作为抗病毒剂的咪唑并[1,2-a]吡啶介离子化合物

  摘要：

  中离子化合物及其类似物作为抗植物病毒剂的应用仍未探索。这是在这个问题上对介离子化合物的抗病毒活性的首次评估。我们的研究涉及设计和合成一系列含有磺酰胺部分的新型咪唑并[1,2- a ]吡啶介离子化合物，并评估它们对马铃薯病毒 Y (PVY) 的抗病毒活性。化合物A33在三维定量构效关系（3D-QSAR）模型分析的基础上进行了评估，在 500 mg/L 时对 PVY 表现出良好的治疗、保护和灭活活性效果，分别高达 51.0、62.0 和 82.1%，分别高于商业宁南霉素（NNM，分别为 47.2、50.1 和 81.4%）。值得注意的是，防御酶活性和蛋白质组学结果表明，化合物A33可以通过激活防御酶的活性来增强防御反应，诱导烟草的糖酵解/糖异生途径抵抗PVY感染。因此，我们的研究表明化合物A33可用作潜在的病毒抑制剂。

  DOI：

  10.1021/acs.jafc.2c01813

文献信息

• INDOL-2-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES
  申请人：Nettekoven Matthias

  公开号：US20080188484A1

  公开（公告）日：2008-08-07

  The present invention relates to compounds of formula I wherein A and R 1 to R 4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

  本发明涉及公式I的化合物，其中A和R1至R4如描述和声明中所定义，并且其药学上可接受的盐。这些化合物可用于治疗和/或预防与H3受体调节相关的疾病。
• Novel Derivatives
  申请人：Heer Jag Paul

  公开号：US20100016330A1

  公开（公告）日：2010-01-21

  The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Ca v 2.2 calcium channels is beneficial.

  本发明涉及新颖的哌嗪衍生物；其制备方法；含有这些衍生物的药物组合物；以及利用这些衍生物在治疗中治疗阻断Ca v 2.2钙通道有益的疾病。
• PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS
  申请人：Heer Jag Paul

  公开号：US20130072499A1

  公开（公告）日：2013-03-21

  The present invention relates to novel piperazine compounds; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Ca v 2.2 calcium channels is beneficial and to treat diseases for which blocking the Ca v 2.2 and Ca v 3.2 calcium channels is beneficial, e.g. to treat pain.

  本发明涉及新型哌嗪化合物；含有这些化合物的药物组合物；以及利用这些化合物在治疗中治疗阻断Ca v 2.2钙通道有益的疾病，以及治疗阻断Ca v 2.2和Ca v 3.2钙通道有益的疾病，例如治疗疼痛。
• [EN] PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS<br/>[FR] DÉRIVÉS DE PIPÉRAZINE POUR BLOQUER DES CANAUX CALCIQUES CAV2.2
  申请人：CONVERGENCE PHARMACEUTICALS

  公开号：WO2011086377A1

  公开（公告）日：2011-07-21

  The present invention relates to novel piperazine compounds; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial and to treat diseases for which blocking the Cav2.2 and Cav3.2 calcium channels is beneficial, e.g. to treat pain.

  本发明涉及新型哌嗪化合物；含有这些化合物的药物组合物；以及利用这些化合物在治疗中对治疗阻断Cav2.2钙通道有益的疾病和对治疗阻断Cav2.2和Cav3.2钙通道有益的疾病，例如治疗疼痛。
• Synthesis of Novel Benzamide- piperazine-sulfonamide Hybrids as Potential Anticancer Agents
  作者：B. Ramalingeswara Rao、Mohana Rao Katiki、Dileep Kommula、SaiShyam Narayanan、Ruby John Anto、M. S. R. Murty

  DOI：10.5562/cca3535

  日期：——

  The synthesis of a series of substituted hippuric acid (2-benzamidoacetic acid) derivatives containing arylsulfonylpiperazine nucleus (3a–j, 4a–j) is described. The compounds were synthesized by coupling hippuric/4-fluorohippuric acid with various arylsulfonylpiperazines using N-(3-dimethylaminopropyl)-N-ethylcarbodiimide (EDCI). The structures of all the new compounds were confirmed by IR, NMR and MS spectral data. All the synthesized compounds have been evaluated for their in vitro cytotoxicity towards five human cancer cell lines of different origins viz. HeLa (Cervical), A549 (Lung), A375 (Skin), MD-AMB-231(Breast) and T98G (brain) and their IC50 values were determined. Among the compounds tested, 3b, 3d, 3g, 4c and 4e displayed significant cytotoxic activity (IC50 = 24.2–38.2 µM). T98G was the most sensitive cell line towards the compounds studied followed by HeLa, A375, A549 and MD-AMB-231.

  一系列取代的苯甲酰基氨基乙酸（2-苯甲酰胺基乙酸）衍生物合成了含有芳基磺酰基哌嗪核（3a-j，4a-j）。这些化合物是通过使用N-(3-二甲基氨基丙基)-N-乙基碳二亚胺（EDCI）将苯甲酰基/4-氟苯甲酰基酸与各种芳基磺酰基哌嗪偶联合成的。所有新化合物的结构均通过红外光谱、核磁共振和质谱数据得到确认。所有合成的化合物均已评估其对五种不同来源的人类癌细胞系（即宫颈癌HeLa，肺癌A549，皮肤癌A375，乳腺癌MD-AMB-231和脑癌T98G）的体外细胞毒性，并确定了它们的IC50值。在测试的化合物中，3b、3d、3g、4c和4e显示出显著的细胞毒性活性（IC50 = 24.2-38.2 µM）。T98G是对所研究的化合物最敏感的细胞系，其次是HeLa、A375、A549和MD-AMB-231。